IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Studies show that administration of interferon (IFN)-alpha causes a significant increase in depressive symptoms. The enzyme indoleamine 2,3-dioxygenase (IDO), which converts tryptophan (TRP) into kynurenine (KYN) and which is stimulated by proinflammatory cytokines, may be implicated in the development of IFN-alpha-induced depressive symptoms, first by decreasing the TRP availability to the brain and second by the induction of the KYN pathway resulting in the production of neurotoxic metabolites. Sixteen patients with chronic hepatitis C, free of psychiatric disorders and eligible for IFN-alpha treatment, were recruited. Depressive symptoms were measured using the Montgomery Asberg Depression Rating Scale (MADRS). Measurements of TRP, amino acids competing with TRP for entrance through the blood-brain barrier, KYN and kynurenic acid (KA), a neuroprotective metabolite, were performed using high-performance liquid chromatography. All assessments were carried out at baseline and 1, 2, 4, 8, 12 and 24 weeks after treatment was initiated. The MADRS score significantly increased during IFN-alpha treatment as did the KYN/TRP ratio, reflecting IDO activity, and the KYN/KA ratio, reflecting the neurotoxic challenge. The TRP/CAA (competing amino acids) ratio, reflecting TRP availability to the brain, did not significantly change during treatment. Total MADRS score was significantly associated over time with the KYN/KA ratio, but not with the TRP/CAA ratio. Although no support was found that IDO decreases TRP availability to the brain, this study does support a role for IDO activity in the pathophysiology of IFN-alpha-induced depressive symptoms, through its induction of neurotoxic KYN metabolites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cytokine-induced activation of the enzyme, indolamine 2,3 dioxygenase (IDO), which metabolizes tryptophan to kynurenine and quinolinic acid, is believed to contribute to reduced availability of serotonin.16,23,24”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [24]
In the citing paper
“Following IDO activation, both the reduced peripheral availability of tryptophan (putatively leading to reduced serotonin synthesis in the brain) and the production of neurotoxic tryptophan metabolites are considered essential steps in the pathophysiological processes.”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“3-hydroxykynurenine and quinolinic acid are NMDA receptor agonists, potentially neurotoxic and thus potentially contributing to depression”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“which converts tryptophan into kynurenine (KYN), a precursor of 3-hydroxykynurenine, a neurotoxic metabolite, and kynurenic acid, a neuroprotective metabolite”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“kynurenic acid is an N-methyl d-aspartate (NMDA) receptor antagonist, and is generally considered neuroprotective”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Research works printed but not linked: 2
- Maes M, Meltzer H . The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, (eds) Psychopharmacology. Raven Press: New York, 1995 pp 933–944.
- Stockmeier CA, Mahajan G, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Neuronal and glial density is increased and neuronal soma size is decreased in the hippocampus in major depressive disorder (MDD). Biol Psychiatry 2003; 53S: 198.
Cited by
Items 201–300 of 445
Fontana, R. J., Kronfol, Z., Lindsay, K. L., Bieliauskas, L. A., Padmanabhan, L., Back-Madruga, C., Lok, A. S. F., Stoddard, A. M., & the HALT-C Trial Group (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02106.x · Cited by 43
Tryptophan Intake and Metabolism in Older Adults with Mood Disorders
Chojnacki, C. J., Popławski, T., Chojnacki, J., Fila, M., Konrad, P., & Błasiak, J. (2020) · Nutrients · doi:10.3390/nu12103183 · Cited by 46
A Review of Sleep Disturbance in Hepatitis C
Sockalingam, S., Abbey, S. E., Alosaimi, F., & Novak, M. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181b314ea · Cited by 40
Yang, J., Rui, B.-B., Chen, C., Chen, H., Xu, T., Xu, W. P., & Wei, W. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.016 · Cited by 49
“…hypothesis, recent studies have focused on potential mechanisms that may link inflammation-induced depression to tryptophan (TRP) metabolism, particularly in the brain, where the breakdown of TRP could reduce the bioavailability of serotonin (5-HT) (Widner et al., 2002; Fitzgerald et al., 2008).”
van den Ameele, S., van Nuijs, A. L. N., Lai, F. Y., Schuermans, J., Verkerk, R. M., van Diermen, L., Coppens, V., Fransén, E., de Boer, P., Timmers, M., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12814 · Cited by 43
Self-citationLaugeray, A., Launay, J.-M., Callebert, J., Mutlu, O., Guillemin, G. J., Belzung, C., & Barone, P. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164337 · Cited by 40
Quelhas, R., & Lopes, A. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358313.06858.ea · Cited by 46
Heinze, S., Egberts, F., Rötzer, S., Volkenandt, M., Tilgen, W., Linse, R., Boettjer, J., VOGT, T. M., Spieth, K., Eigentler, T., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b8bdb9 · Cited by 42
“In addition, the production of neurotoxic metabolites of kynurenine such as 3-hydroxykynurenine and quinolinic acid might increase and contribute to IFN-a induced psychopathology.(59,60) Further mechanisms are an increase of cortisol and glucocorticoid receptors,(61,62) changes of cytokines,(57,63,64) in increase of c…”
BackgroundBacking into the future: pharmacological approaches to the management of resistant depression
Cowen, P. J. (2017) · Psychological Medicine · doi:10.1017/s003329171700068x · Cited by 40
“…is also possible that inflammation induced activation of the tryptophan metabolising enzyme, IDO (indoleamine 2,3-dioxygenase), would have the effect of lowering tryptophan availability for serotonin synthesis and also producing neurotoxic metabolites such as quinolinic acid (Wichers et al. 2005).”
BackgroundFontana, R. J., Bieliauskas, L. A., Lindsay, K. L., Back‐Madruga, C., Wright, E. C., Snow, K. K., Lok, A. S. F., Kronfol, Z., & Padmanabhan, L. (2007) · Hepatology · doi:10.1002/hep.21633 · Cited by 38
Dexamethasone Induces a Specific Form of Ramified Dysfunctional Microglia
Park, M.-J., Park, H.-S., You, M., Yoo, J., Kim, S. H., & Kwon, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1156-z · Cited by 44
Franklin, M., Bermúdez, I., Murck, H., Singewald, N., & Gaburro, S. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.10.003 · Cited by 40
“Hence the increased K/KA ration may be a causal factor in depression as demonstrated by interferon treatment used in patients with chronic hepatitis C infection (Wichers et al., 2005).”
BackgroundBarreto, F. S., Filho, A. J. M. C., Araújo, M. C., de Moraes, M. O., de Moraes, M. E. A., Maes, M. H. J., de Lucena, D. F., & Macêdo, D. S. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000384 · Cited by 39
Self-citationKorte-Bouws, G. A. H., Albers, E., Voskamp, M. J., Hendriksen, H., de Leeuw, L. R., Güntürkün, O., de Roock, S., Vastert, S. J., & Korte, S. M. (2019) · Pharmaceuticals · doi:10.3390/ph12010009 · Cited by 40
Immunologische Aspekte bei depressiven Störungen
Müller, N., & Schwarz, M. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2311-3 · Cited by 48
Mahmoud, M. E., Fereig, R. M., & Nishikawa, Y. (2017) · Infection and Immunity · doi:10.1128/iai.00007-17 · Cited by 39
“IDO catabolizes Trp into the neurotoxic metabolites kynurenine (Kyn) and kynurenic acid (12, 13).”
BackgroundMiura, H., Ozaki, N., Shirokawa, T., & Isobe, K. (2008) · Stress · doi:10.1080/10253890701685908 · Cited by 37
“Recent studies have suggested that changes in the balance between the activity of the KYN pathway and that of the 5-HT pathway in TRP metabolism play an important role in depression (Wichers et al. 2005; Myint et al. 2007).”
BackgroundPRANDOTA, J. (2007) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000208272.42379.aa · Cited by 40
Ehret, M. J., & Sobieraj, D. M. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12268 · Cited by 40
Schäfer, A., Scheurlen, M., Seufert, J., Keicher, C., Weißbrich, B., Rieger, P., & Kraus, M. R. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.007 · Cited by 36
“Therefore, it might be speculated that 5-HT metabolism is only one among many pathways [23,24], explaining to some extent the absence of a clear relationship between peripheral 5-HT levels and IFN-induced depression.”
BackgroundRole of paroxetine in interferon-α-induced immune and behavioural changes in male Wistar rats
Myint, A. M., O'Mahony, S., Kubera, M., Kim, Y. K., Kenny, C., Kaim-Basta, A., Steinbusch, H. W. M., & Leonard, B. E. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077165 · Cited by 33
Association between increased tryptophan degradation and depression in cancer patients
Kurz, K., Schroecksnadel, S., Weiss, G., & Fuchs, D. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328340d849 · Cited by 36
Pawłowski, T., Pawlak, D., Inglot, M., Zalewska, M., Marciniak, D. M., Bugajska, J., Janocha‐Litwin, J., & Małyszczak, K. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.190139 · Cited by 37
Pain, Depression and Inflammation: Are Interconnected Causative Factors Involved?
Leonard, B. E. (2015) · Modern trends in psychiatry · doi:10.1159/000435930 · Cited by 36
Safety, Tolerability, and Immunogenicity of Interferons
Tovey, M. G., & Lallemand, C. (2010) · Pharmaceuticals · doi:10.3390/ph3041162 · Cited by 42
“Several studies have also shown that IFN can cause changes in the electrophysiological activity of the brain [64,102-108].”
Backgroundde Klerk, O. L., Bosker, F. J., Willemsen, A. T. M., van Waarde, A., Visser, A. K. D., de Jager, T., Dagytė, G., den Boer, J. A., Dierckx, R., & Meerlo, P. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109349840 · Cited by 36
“Depressive disorders have been linked to neuro-inflammatory events, wherein pro-inflammatory cytokines, acute phase proteins and possible endotoxic substances easily cross the BBB due to an increased permeability (Maletic et al., 2007; Wichers et al., 2005).”
BackgroundMiura, H., Ando, Y., Noda, Y., Isobe, K., & Ozaki, N. (2011) · Stress · doi:10.3109/10253890.2010.541539 · Cited by 34
“Activation of the KYN pathway by proinflammatory cytokines induces depressive symptoms (Bonaccorso et al. 2002; Capuron et al. 2002, 2003; Wichers et al. 2005).”
BackgroundWang, W., Voss, K., Liu, J., & Gordeev, M. F. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00524 · Cited by 33
Kynurenine pathway changes in late-life depression with memory deficit
Wu, Y., Mai, N., Zhong, X., Wen, Y., Zhou, Y., Li, H., Shang, D., Hu, L., Chen, X., Chen, B., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.041 · Cited by 32
Inamdar, A., Pich, E. M., Gee, M., Makumi, C. W., Mistry, P. C., Robertson, J., Steinberg, E., Zamuner, S., Learned, S. M., Alexander, R., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114529377 · Cited by 32
“This sickness syndrome has been observed in subjects treated with interferon α (Prather et al., 2009; Raison et al., 2006; Wichers et al., 2005), endotoxin (Reichenberg et al., 2001), or influenza virus vaccination (Glaser et al., 2003).”
BackgroundDuda, W., Curzytek, K., Kubera, M., Connor, T. J., Fagan, E. M., Basta‐Kaim, A., Trojan, E., Papp, M., Gruca, P., Budziszewska, B., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.039 · Cited by 34
Self-citationTheis, N., Brown, M. A., Wood, P., & Waldron, M. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa006 · Cited by 38
Structural variants of IFNα preferentially promote antiviral functions
Vázquez, N., Schmeisser, H., Dolan, M. A., Bekisz, J., Zoon, K. C., & Wahl, S. M. (2011) · Blood · doi:10.1182/blood-2010-12-325027 · Cited by 32
“From HY4, sitedirected mutant-1 (SDM1):IFN 21b(1-75)/IFN 2c(76-81)/IFN 21b(8295)/IFN 2c,(96-166) S86- Y, SDM2: IFN 21b(1-75)/IFN 2c(76-81)/ IFN 21b(82-95)/IFN 2c, (96-166) N90- Y; and Cassette mutant (CM3): IFN 21b(1-75)/IFN 2c(76-81)/IFN 21b(82-95)/IFN 2c(96166), S86K17,21.”
MethodKumar, V., Rudra, A., Sreedhara, M. V., Subramani, T. S., Prasad, D. S., Das, M. L., Murugesan, S. V., Yadav, R., Trivedi, R. K., Louis, J. V., et al. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.06.205 · Cited by 31
“…significant elevation (12-fold; p < 0.01) (2.64 vs 31.7 nmoles/h/mg protein) in lung IDO activity on day 14, consistent with previous reports showing a correlation between the time course of development of depression-like behaviors and lung IDO activity (Moreau et al., 2008; Wichers et al., 2005).”
ResultInfluentialFrom “Leaky Gut” to Impaired Glia-Neuron Communication in Depression
Rudzki, L., & Maes, M. H. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_9 · Cited by 33
Self-citationCancer cachexia: molecular mechanism and pharmacological management
Li, Y., Jin, H., Chen, Y., Huang, T., Mi, Y., & Zou, Z. (2021) · Biochemical Journal · doi:10.1042/bcj20201009 · Cited by 32
Association Between Tryptophan Metabolites, Physical Performance, and Frailty in Older Persons
Saedi, A. A., Chow, S., Vogrin, S., Guillemin, G. J., & Duque, G. (2022) · International Journal of Tryptophan Research · doi:10.1177/11786469211069951 · Cited by 34
Coccaro, E. F., Lee, R., Fanning, J. R., Fuchs, D., Goiny, M., Erhardt, S., Christensen, K. R., Brundin, L., & Coussons‐Read, M. E. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.04.024 · Cited by 34
“In other studies, similar treatment with INF-α increases cerebrospinal fluid (CSF) KYN (but not CSF TRP) levels and correlates with level of depressive symptoms (Raison et al., 2010; Wichers et al., 2005).”
ResultPsychiatric management of the hepatitis C patient
Rifai, M. A., Indest, D. W., Loftis, J. M., & Hauser, P. (2006) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-006-0007-6 · Cited by 30
Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Rahola, J. G. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604533 · Cited by 32
“Another common characteristic shared by depression and inflammation is IDO (indoleamine 2,3-dioxygenase) activation, an enzyme that induces the catabolism of tryptophan into TRYCATs (tryptophan catabolites along the IDO pathway), such as kynurenine with the consequent increase in TRYCATs [124-126].”
BackgroundInterferon α subtypes in HIV infection
Sutter, K., Dickow, J., & Dittmer, U. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.02.002 · Cited by 29
Soichot, M., Hennart, B., Saabi, A. A., Leloire, A., Froguel, P., Lévy‐Marchal, C., Poulain‐Godefroy, O., & Allorge, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025470 · Cited by 31
“treated patients [15,25,26].”
Regan, T. W., Gill, A. C., Clohisey, S., Barnett, M. W., Pariante, C. M., Harrison, N. A., Hume, D. A., Bullmore, E. T., & Freeman, T. C. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0617-261r · Cited by 29
Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets
Herman, F. J., Simkovic, S. J., & Pasinetti, G. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14569 · Cited by 29
Zhang, S., Zong, Y., Ren, Z., Hu, J., Wu, X., Xiao, H., Qin, S., Zhou, G., Ma, Y., Zhang, Y., et al. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15016 · Cited by 29
Molecular mechanisms underlying major depressive disorder and post-stroke affective disorders
Coliță, D., Burdusel, D., Glăvan, D., Hermann, D. M., Coliță, C.-I., Coliță, E., Udriștoiu, I., & Popa‐Wagner, A. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.037 · Cited by 28
Chen, W., Liu, S., Chen, F., Zhou, C.-J., Yu, J., Zhuang, C., Shen, X., Chen, B., & Yu, Z. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00599 · Cited by 29
Kynurenine pathway changes in late-life depression
Wu, Y., Zhong, X., Mai, N., Wen, Y., Shang, D., Hu, L., Chen, B., Zhang, M., & Ning, Y. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.007 · Cited by 28
Chojnacki, C. J., Konrad, P., Błońska, A., Mędrek-Socha, M., Przybyłowska-Sygut, K., Chojnacki, J., & Popławski, T. (2022) · Nutrients · doi:10.3390/nu14153217 · Cited by 35
Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments
Suseelan, S., & Pinna, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.09.001 · Cited by 33
Shiokawa, Z., Kashiwabara, E., Yoshidome, D., Fukase, K., Inuki, S., & Fujimoto, Y. (2016) · ChemMedChem · doi:10.1002/cmdc.201600446 · Cited by 27
Individualized Immunological Data for Precise Classification of OCD Patients
Lamothe, H., Baleyte, J., Smith, P., Pélissolo, A., & Mallet, L. (2018) · Brain Sciences · doi:10.3390/brainsci8080149 · Cited by 28
Dantas, R. L., Freff, J., Ambrée, O., Beins, E. C., Forstner, A. J., Dannlowski, U., Baune, B. T., Scheu, S., & Alferink, J. (2021) · Cells · doi:10.3390/cells10040941 · Cited by 32
“Psychopathological symptoms were associated with increased IDO activity measured indirectly by quantifying kynurenine, a neurotoxic metabolite produced by IDO [100].”
BackgroundRengasamy, M. L., Marsland, A. L., Spada, M. L., Hsiung, K. S., Kovats, T., & Price, R. B. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100177 · Cited by 32
“…studies typically do not demonstrate reduction in CNS tryptophan and serotonin concentrations with kynurenine pathway activation, consistent with studies showing dichotomy of kynurenine pathway activation and CNS tryptophan depletion (Hughes et al., 2012; Raison et al., 2010; Wichers et al., 2005).”
Zhang, K., Lei, N., Li, M., Li, J., Caijun, L., Shen, Y. L., Guo, P., Xiong, L., & Xie, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.791991 · Cited by 29
Ye, F., Dong, M.-C., Xu, C.-X., Jiang, N., Chang, Q., Liu, X., & Pan, R. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176301 · Cited by 33
Fuxé, K., Borroto‐Escuela, D. O., Tarakanov, A. O., Romero‐Fernandez, W., Manger, P. R., Rivera, A., Craenenbroeck, K. V., Skieterska, K., Díaz-Cabiale, Z., Filip, M., et al. (2013) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2013.10.002 · Cited by 28
Neurologic Complications of Chemotherapy
Dietrich, J., & Wen, P. Y. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-412-4_17 · Cited by 26
Brain derived neurotrophic factor deficiency exacerbates inflammation-induced anhedonia in mice
Parrott, J. M., Porter, G. A., Redus, L., & O’Connor, J. C. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105404 · Cited by 29
Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Breitenecker, R. J., Rothenhäusler, H., Robier, C., Baranyi, M., Theokas, S., & Meinitzer, A. (2017) · PeerJ · doi:10.7717/peerj.3968 · Cited by 30
“The clinical relevance of the inflammatory hypothesis of depression is not fully understood and subject to controversy (Wichers et al., 2005; Savitz et al., 2015; Dantzer et al., 2008).”
BackgroundInfluentialGool, A. R. V., Verkerk, R. M., Fekkes, D., Bannink, M., Sleijfer, S., Kruit, W. H. J., van der Holt, B., Scharpé, S., Eggermont, A. M. M., Stoter, G., et al. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01854.x · Cited by 25
Self-citationHall, S., Arora, D. S., Anoopkumar‐Dukie, S., & Grant, G. D. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b03568 · Cited by 23
Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Breitenecker, R. J., Stojaković, T., März, W., Robier, C., Rothenhäusler, H., Mangge, H., & Meinitzer, A. (2017) · Scientific Reports · doi:10.1038/srep43642 · Cited by 24
“Exclusion criteria for all participants were (1) pregnancy, (2) significant comorbid conditions, (3) diagnosis of a neurological disease, and (4) for the patients with HCV infection, a coincidence with other chronic liver diseases.”
BackgroundNikkheslat, N., Pariante, C. M., & Zunszain, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00003-9 · Cited by 27
Zahiu, C. D. M., & Rimbas, M. (2014) · Europe PMC (PubMed Central) · Cited by 24
Pawłowski, T., Małyszczak, K., Inglot, M., Zalewska, M., Radkowski, M., Laskus, T., & Pawlak, D. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.06.004 · Cited by 22
Methylphenidate ameliorates the homeostatic balance between levels of kynurenines in ADHD children
Molina‐Carballo, A., Cubero-Millán, I., Fernández-López, L., Checa-Ros, A., Machado-Casas, I., Jerez-Calero, A. E., Blanca-Jover, E., Cantarero-Malagón, S., Uberos, J., & Muñoz‐Hoyos, A. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114060 · Cited by 23
Why are neurotransmitters neurotoxic? An evolutionary perspective
Harris, K. D., Weiss, M., & Zahavi, A. A. (2014) · F1000Research · doi:10.12688/f1000research.4828.2 · Cited by 25
A concise preparation of the non-proteinogenic amino acid l-kynurenine
Kleijn, L. H. J., Müskens, F. M., Oppedijk, S. F., de Bruin, G., & Martin, N. I. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.09.055 · Cited by 21
Duan, K., Wang, S., Yin, J., Li, X., Ma, J., Huang, Z., Zhou, Y., Yu, H., Yang, M., Zhou, H., et al. (2018) · Archives of Women s Mental Health · doi:10.1007/s00737-018-0898-y · Cited by 22
Decoding serotonin: the molecular symphony behind depression
Shu, Y. L., Tian, L., Wang, X., Meng, T., Yu, S., & Li, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1572462 · Cited by 28
The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol
dos Santos, A. H., Vila-Verde, C., Guimarães, F. S., Joca, S. R. L., & Lisboa, S. F. D. S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411101217 · Cited by 23
“At first, inflammatory conditions, or treatment with immune system stimulants, such as interferons, induce sickness behavior, increase peripheral and SNC inflammation signs, and seem to contribute to the onset of psychiatric disorders [5-8].”
Disturbances of Tryptophan Metabolism and Risk of Depression in HCV Patients Treated with IFN-Alpha
Oxenkrug, G., Turski, W. A., Zgrajka, W., Jv, W., Ruthazer, R., & D, P. S. M. (2014) · Journal of Infectious Diseases and Therapy · doi:10.4172/2332-0877.1000131 · Cited by 20
“In addition to serotonin deficiency, suggested as one of the mechanisms of depression [4,5], increased formation of KYN and its neuroactive derivatives contribute to mechanisms of depression as well [6,7].”
BackgroundInflammation and its relevance to psychiatry
Cavanagh, J., & Mathias, C. (2008) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.106.003319 · Cited by 24
“Recent research suggests that alpha interferon may exert its effects by altering tryptophan metabolism (Wichers et al, 2005).”
Yang, S., Han, J., Ye, Z., Zhou, H., Yan, Y., Han, D., Chen, S., Wang, L., Feng, Q., Zhao, X., et al. (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-024-02579-4 · Cited by 24
“KYN/TRP and 3-HK/KYN represent the enzymatic activity of two key enzymes — IDO and KMO respectively in TKP [44].”
Chávez-Castillo, M., Nava, M., Ortega, Á., Rojas, M., Núñez, V., Salazar, J. J., Bermúdez, V., & Rojas, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200413144401 · Cited by 24
“In patients with hepatitis C undergoing therapy with IFN-α for 24 weeks, this treatment was associated not only with increased depressive symptoms, but also increased KYN/tryptophan ratios, reflecting higher IDO activity, as well as increased KYN/KA ratios, corresponding to the degree of neurotoxicity involved [61].”
BackgroundEarly Life Stress and the Fate of Kynurenine Pathway Metabolites
Coplan, J. D., George, R., Syed, S. A., Rozenboym, A. V., Tang, J. E., Fulton, S. L., & Perera, T. D. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.636144 · Cited by 23
“Recent advances have elucidated a role for the immune system, which is now recognized to be an instrumental component to cause depression from neurotoxicity rather than tryptophan depletion (Wichers et al., 2005), and although modest tryptophan decreases have been associated with depression, these occur independent of…”
BackgroundVasiliu, O. (2023) · Pharmaceuticals · doi:10.3390/ph16030411 · Cited by 22
Cremone, I. M., Nardi, B., Amatori, G., Palego, L., Baroni, D., Casagrande, D., Massimetti, E., Betti, L., Giannaccini, G., Dell’Osso, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061600 · Cited by 22
Microbes and Mental Illness: Past, Present, and Future
Bransfield, R. C., Mao, C., & Greenberg, R. (2023) · Healthcare · doi:10.3390/healthcare12010083 · Cited by 30
“…in an enzyme, indoleamine 2,3-dioxygenase (IDO), that shifts the conversion of tryptophan away from serotonin, melatonin, and kynurenic acid (a neuroprotective compound) and instead pushes the conversion to quinolinic acid, which is a neurotoxin and an N-methyl-D-aspartate (NMDA) agonist [380].”
BackgroundTargeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer’s disease
Gong, C.-Y., Li, Z., Wang, H., Liu, J., Chen, L., Zhang, H.-W., Wang, X., & Yang, J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.05.022 · Cited by 21
“) [8].”
BackgroundKoola, M. M., Nikiforuk, A., Pillai, A., & Parsaik, A. K. (2018) · PubMed · Cited by 32
Zhao, Y. H., Sun, X., Zhang, T., Liu, S., Cai, E., & Zhu, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111387 · Cited by 21
Almulla, A. F., Thipakorn, Y., Zhou, B., Vojdani, A., Paunova, R., & Maes, M. H. J. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.10.021 · Cited by 23
Self-citationInflammation, Neurotoxins and Psychiatric Disorders
Myint, A.-M. (2013) · Modern trends in psychiatry · doi:10.1159/000343968 · Cited by 19
Teraishi, T., Hori, H., Sasayama, D., Matsuo, J., Ogawa, S., Ota, M., Hattori, K., Kajiwara, M., Higuchi, T., & Kunugi, H. (2015) · Scientific Reports · doi:10.1038/srep15994 · Cited by 19
COVID-19, interferons, and depression: A commentary
Shader, R. I. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113198 · Cited by 18
Manéglier, B., Rogez‐Kreuz, C., Spreux‐Varoquaux, O., Malleret, B., Thérond, P., Samah, B., Drouet, I., Dormont, D., Advenier, C., & Clayette, P. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00460.x · Cited by 21
Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects
Bannink, M., Fekkes, D., Gool, A. R. V., Kruit, W. H. J., Sleijfer, S., van der Holt, B., Eggermont, A. M. M., Stoter, G., & Hengeveld, M. W. (2007) · Neuropsychobiology · doi:10.1159/000108382 · Cited by 20
Belle, L., Zhou, V., Stuhr, K. L., Beatka, M. J., Siebers, E. M., Knight, J. M., Lawlor, M. W., Weaver, C. T., Hashizume, M., Hillard, C. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93726 · Cited by 18
“IDO-1, which catalyzes the conversion of tryptophan to metabolites that can be neurotoxic (54, 55), is an important downstream pathway by which the inflammatory effects of IL-6 are mediated in the brain.”
BackgroundBaranyi, A., Meinitzer, A., Rothenhäusler, H., Amouzadeh-Ghadikolai, O., von Lewinski, D., Breitenecker, R. J., & Herrmann, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208238 · Cited by 17
Pan, Y., Luo, R., Zhang, S., Liu, Y., Wang, Y., Feng, S., & Li, H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.080 · Cited by 19
Bai, J., Eldridge, R. C., Houser, M. C., Martin, M., Powell, C., Sutton, K. S., Noh, H. I., Wu, Y., Olson, T. A., Konstantinidis, K. T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05066-1 · Cited by 22
Pekary, A. E., Stevens, S. A., & Sattin, A. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn:31:03:245 · Cited by 16
Casaril, A. M., Domingues, M., Lourenço, D. D. A., Vieira, B. M., Begnini, K. R., Corcini, C. D., França, R. T., Varela, A. S., Seixas, F. K., Collares, T. V., et al. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109278 · Cited by 17
Psychological and biological mechanisms of cytokine induced depression
Hepgul, N., Mondelli, V., & Pariante, C. M. (2010) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000774 · Cited by 19
“Again, these effects are present in all patients, but patients with IFN-α-induced depression show even lower levels of serum tryptophan and serotonin, and even higher levels of serum tryptophan metabolites (Bonaccorso et al., 2002; Wichers et al., 2005).”
BackgroundPossible antidepressant mechanism of acupuncture: targeting neuroplasticity
Xu, N., He, Y., Wei, Y.-N., Bai, L., & Wang, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1512073 · Cited by 20
Pelgrim, C. E., van Ark, I., van Berkum, R. E., Schuitemaker-Borneman, A. M., Flier, I., Leusink-Muis, T., Janbazacyabar, H., Diks, M. A. P., Gosker, H. R., KELDERS, M. C. J. M., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1010989 · Cited by 16
“Inflammation can induce depression by lowering tryptophan levels through, among others, the upregulation of IDO activity, and ultimately decrease serotonin production in the brain (98, 99).”
BackgroundImipramine reverses depressive-like parameters in pneumococcal meningitis survivor rats
Barichello, T., Milioli, G., Generoso, J. S., Cipriano, A. L., da Costa, C. S., Moreira, A. P., Vilela, M. C., Comim, C. M., Teixeira, A. L., & Quevedo, J. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0749-8 · Cited by 14
Psychiatric Disorders - Worldwide Advances
Uehara, T. (2011) · InTech eBooks · doi:10.5772/1289 · Cited by 16
Metadata
- Authors
- Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M.
- Affiliations
- Maastricht University (NL)
- Maastricht University Medical Centre (NL)
- Ziekenhuis Oost-Limburg (BE)
- University of Antwerp (BE)
- Corresponding author
- Wichers, M C
- Venue
- Molecular Psychiatry
- Published
- 2004-10-19
- Volume
- 10
- Issue
- 6
- Pages
- 538-544
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2078660110
- Cited by
- 445
- References
- 54
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 15 · 2021: 28 · 2020: 23 · 2019: 17 · 2018: 31 · 2017: 20 · 2016: 30 · 2015: 24 · 2014: 17 · 2013: 26 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- indoleamine 2,3-dioxygenase, interferon-alpha, depressive symptoms, tryptophan depletion, kynurenine pathway, kynurenic acid, neurotoxicity, chronic hepatitis C, blood-brain barrier, tryptophan availability, inflammatory cytokines
- MeSH terms
- Adult, Depression, Female, Follow-Up Studies, Humans, Immunotherapy, Kynurenic Acid, Kynurenine, Male, Middle Aged, Psychiatric Status Rating Scales, Tryptophan, Interferon-alpha, Hepatitis C, Chronic, Dioxygenases, Indoleamine-Pyrrole 2,3,-Dioxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.